<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532116</url>
  </required_header>
  <id_info>
    <org_study_id>S9303-P0601</org_study_id>
    <nct_id>NCT00532116</nct_id>
  </id_info>
  <brief_title>PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly</brief_title>
  <official_title>Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Somerset Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Somerset Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of age on the PK of two different doses of EMSAM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Proportionality of PK parameters and EMSAM release characteristics.</measure>
    <time_frame>33 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EMSAM 6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EMSAM (Selegiline Transdermal System) 12mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMSAM (Selegiline Transdermal System) 6mg</intervention_name>
    <description>STS 6mg/24hr</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMSAM (Selegiline Transdermal System) 12mg</intervention_name>
    <description>EMSAm 12mg/24Hr</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female, 18 to 45years of age (inclusive) and 65 years of age or older.&#xD;
&#xD;
          2. Non-obese as defined by being within 15% of desirable body weight for frame size&#xD;
             (Appendix II).&#xD;
&#xD;
          3. In general good health as ascertained by physical examination (PE) including&#xD;
             measurement of supine and standing vital signs, medical history, clinical laboratory&#xD;
             studies, and 12-lead electrocardiogram (ECG).&#xD;
&#xD;
          4. Females must have a negative serum pregnancy test during screening confirmed by a&#xD;
             negative urine pregnancy screen at the baseline visit. Women of childbearing potential&#xD;
             must agree to continuously use a medically acceptable method of birth control during&#xD;
             the course of the study. Acceptable birth control methods are hormonal contraceptives,&#xD;
             intrauterine devices or double barrier method (a combination of condom plus&#xD;
             contraceptive foam). Postmenopausal females will be eligible to participate if their&#xD;
             last normal menses was at least one (1) year prior to study entry.&#xD;
&#xD;
          5. Able and willing to provide informed consent.&#xD;
&#xD;
          6. Able and willing to follow a modified diet.&#xD;
&#xD;
          7. Able and willing to follow the requirements of the study; willing to wear a patch, no&#xD;
             swimming, no excessive exercise, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of significant acute or chronic medical disorder that might complicate or&#xD;
             interfere with MAO inhibitor therapy, such as:&#xD;
&#xD;
               1. Any cardiovascular or cardiac condition requiring drug treatment. Upon review&#xD;
                  with Sponsor, subjects with well controlled hypertension or hyperlipidemia will&#xD;
                  be allowed.&#xD;
&#xD;
               2. History of symptomatic orthostatic hypotension, or in the investigator's best&#xD;
                  clinicaljudgment a clinically significant postural decrease in systolic blood&#xD;
                  pressure at screening or baseline.&#xD;
&#xD;
               3. Type I diabetes mellitus, or poorly controlled Type II diabetes mellitus.&#xD;
&#xD;
               4. Malignancy and/or chemotherapy within 1 year prior to screening, other than basal&#xD;
                  cell carcinoma. Malignancies more than 1 year may not preclude participation and&#xD;
                  will be reviewed on a case-by-case basis by the Somerset Pharmaceuticals, Inc.,&#xD;
                  medical monitor.&#xD;
&#xD;
               5. Any skin condition (e.g., eczema, psoriasis, dyshydrosis) that might interfere&#xD;
                  with application and adherence of the STS.&#xD;
&#xD;
               6. Known or suspected hypersensitivity to selegiline or other MAO inhibitors.&#xD;
&#xD;
               7. Any significant immunological, pulmonary, hematologic, endocrine and/or metabolic&#xD;
                  disease or disorder or severe or acute medical illness, that is, metastatic&#xD;
                  cancer, brain tumors, decompensated cardiac, hepatic or renal failure.&#xD;
&#xD;
               8. Neurological disorders including delirium, history of head trauma, movement&#xD;
                  disorders, dementia, multiple sclerosis, stroke, within the past 6 months&#xD;
                  preceding the study.&#xD;
&#xD;
          2. Any central nervous system disorder including Alzheimer's disease, Parkinson's&#xD;
             disease, epilepsy, or cerebrovascular disease.&#xD;
&#xD;
          3. Any psychiatric disorders (except personality disorders).&#xD;
&#xD;
          4. Any mood disorder including MDD which is current or relapsed over the past three&#xD;
             years.&#xD;
&#xD;
          5. ADHD.&#xD;
&#xD;
          6. Any conditions that may cause depression including endocrinopathies other than&#xD;
             diabetes, lymphoma, pancreatic cancer.&#xD;
&#xD;
          7. Any other illness or disorder that in the opinion of the Investigator would place the&#xD;
             subject at significant risk or any inability to follow the requirements of the study&#xD;
             regarding maintaining scheduled visits or patch applications.&#xD;
&#xD;
          8. Use of any medication listed below within five half-lives prior to baseline. A longer&#xD;
             period of time may be specifically noted for certain medications as indicated:&#xD;
&#xD;
               1. All contraindicated medications (see Section 7.1.4.3)&#xD;
&#xD;
               2. Psychotropic medication, including centrally active anticholinergics,&#xD;
                  anticonvulsants, antiparkinsonian agents, fluoxetine (5 weeks), MAOIs (2 weeks),&#xD;
                  antipsychotics (oral - 60 days; intramuscular - 10 weeks), anxiolytics,&#xD;
                  vasodilators (exception: Viagra is permitted), cerebral enhancers&#xD;
                  (acetylcholinesterase inhibitors), psychostimulants, lithium carbonate,&#xD;
                  nootropics, reserpine, methyldopa (within 30 days), ergot preparations.&#xD;
&#xD;
               3. Sympathomimetic drugs, e.g., amphetamines, methylphenidate, dopamine,&#xD;
                  epinephrine, norepinephrine, over-the-counter (OTC) and prescription nasal&#xD;
                  decongestants (with the exception of nasal steroids), oral or inhaled&#xD;
                  sympathomimetic bronchodilators (e.g., albuterol [Proventil], Serevent) and&#xD;
                  appetite suppressants.&#xD;
&#xD;
               4. Any serotonergic drug including sumatriptan succinate (Imitrex), zolmitriptan&#xD;
                  (Zomig), cyproheptadine (Periactin), methysergide (Sansert) or other agonists&#xD;
                  or antagonists of serotonin receptors.&#xD;
&#xD;
               5. Meperidine (Demerol), or other opioids.&#xD;
&#xD;
               6. R(-)tryptophan, metoclopramide.&#xD;
&#xD;
               7. St. John's wort / hypericum within two (2) weeks and other herbal supplements&#xD;
&#xD;
               8. Dietary supplements containing tyramine and/or ephedrine.&#xD;
&#xD;
          9. Presence of an Axis-II disorder that makes it unlikely that the subject will be&#xD;
             compliant.&#xD;
&#xD;
         10. Presence or history of bipolar disorder or psychotic disorder.&#xD;
&#xD;
         11. Serious risk of suicide.&#xD;
&#xD;
         12. History of substance abuse, including alcohol abuse as defined by DSM-IV criteria,&#xD;
             within the past 12 months.&#xD;
&#xD;
         13. Current use of tobacco products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <last_update_submitted>September 18, 2007</last_update_submitted>
  <last_update_submitted_qc>September 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2007</last_update_posted>
  <keyword>Healthy</keyword>
  <keyword>Elderly</keyword>
  <keyword>Non Elderly</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selegiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

